A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas

Anaplastic large T-cell lymphoma (ALCL) is an aggressive disease that presents in pediatric or adult patients with advanced stage disease, extranodal involvement, and constitutional symptoms. 1 Approximately 50% of ALCLs are characterized by constitutive activity of the anaplastic lymphoma kinase (ALK) gene because of chromosomal translocations, most frequently a t(2;5) leading to an NPM1-ALK gene fusion. 2 ALK alterations can be detected also in other lymphoma histotypes, histiocytosis, and nonhematological cancers. 2,3 In rare cases, ALK fusions with NPM1 or other partners can be driver events also in diffuse large B-cell lymphoma (DLBCL) and plasmablastic lymphoma (PBL), 4,5 but the optimal management of these rare diseases is unknown. In ALK + ALCLs, anthracycline-based chemotherapy regimens are associated with an overall responserate(ORR)of80%to85% 1 anda3-yearoverallsurvival(OS)of82%isreportedinpatientsattaining complete remission (CR). However, more than 50%of patients relapse and need

[1]  F. Meggetto,et al.  NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target , 2021, Cancers.

[2]  C. Gambacorti-Passerini,et al.  Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy , 2020, American journal of hematology.

[3]  R. Advani,et al.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial , 2019, The Lancet.

[4]  S. Yuen,et al.  ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion , 2018, Modern Pathology.

[5]  F. Gherlinzoni,et al.  Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma , 2017, Haematologica.

[6]  W. Wilson,et al.  International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Higuchi,et al.  Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report , 2016, Case Reports in Oncology.

[8]  C. Gambacorti-Passerini,et al.  Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. , 2016, The New England journal of medicine.

[9]  A. Rossi,et al.  Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas , 2015, PloS one.

[10]  W. Klapper,et al.  Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. , 2014, Blood.

[11]  J. Downing,et al.  ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. , 2003, Blood.

[12]  P. Marynen,et al.  ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. , 2003, Blood.

[13]  A. Shustov,et al.  Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management. , 2018, Cancer treatment and research.